OBJECTIVES: A human protein phosphatase inhibitor-1 polymorphism, G147D (c.440G>A, p.147G>D), has been previously demonstrated to blunt the contractile responses of cardiomyocytes to beta-adrenergic agonists. The present study sought to examine whether the G147D inhibitor-1 polymorphism may be associated with specific clinical characteristics of heart failure carriers. METHODS: Clinical information of 963 heart failure patients was analyzed according to race, inhibitor-1 genotype, treatment with beta-blockers and mortality patterns. RESULTS: The G147D inhibitor-1 genetic variant was found almost exclusively in black subjects and its frequency was similar between normals and heart failure patients, indicating that it was not a primary risk factor for developing heart failure. Comparison of the major cardiac functional parameters and transplant-free survival patterns between carrier and noncarrier patients did not reveal any significant differences. Furthermore, echocardiographic evaluation showed similar outcomes of beta-blocker treatment between G147D carriers and noncarriers. CONCLUSIONS: The present findings indicate that the human inhibitor-1 G147D polymorphism, found almost exclusively in blacks, may act as a modifier rather than risk factor in heart failure development. Copyright 2008 S. Karger AG, Basel.
OBJECTIVES: A humanprotein phosphatase inhibitor-1 polymorphism, G147D (c.440G>A, p.147G>D), has been previously demonstrated to blunt the contractile responses of cardiomyocytes to beta-adrenergic agonists. The present study sought to examine whether the G147Dinhibitor-1 polymorphism may be associated with specific clinical characteristics of heart failure carriers. METHODS: Clinical information of 963 heart failurepatients was analyzed according to race, inhibitor-1 genotype, treatment with beta-blockers and mortality patterns. RESULTS: The G147Dinhibitor-1 genetic variant was found almost exclusively in black subjects and its frequency was similar between normals and heart failurepatients, indicating that it was not a primary risk factor for developing heart failure. Comparison of the major cardiac functional parameters and transplant-free survival patterns between carrier and noncarrier patients did not reveal any significant differences. Furthermore, echocardiographic evaluation showed similar outcomes of beta-blocker treatment between G147D carriers and noncarriers. CONCLUSIONS: The present findings indicate that the humaninhibitor-1G147D polymorphism, found almost exclusively in blacks, may act as a modifier rather than risk factor in heart failure development. Copyright 2008 S. Karger AG, Basel.
Authors: Kersten M Small; Lynne E Wagoner; Albert M Levin; Sharon L R Kardia; Stephen B Liggett Journal: N Engl J Med Date: 2002-10-10 Impact factor: 91.245
Authors: Ali El-Armouche; Torsten Pamminger; Diana Ditz; Oliver Zolk; Thomas Eschenhagen Journal: Cardiovasc Res Date: 2004-01-01 Impact factor: 10.787
Authors: Ali El-Armouche; Thomas Rau; Oliver Zolk; Diana Ditz; Torsten Pamminger; Wolfram-H Zimmermann; Elmar Jäckel; Sian E Harding; Peter Boknik; Joachim Neumann; Thomas Eschenhagen Journal: FASEB J Date: 2003-01-02 Impact factor: 5.191
Authors: Kobra Haghighi; Fotis Kolokathis; Luke Pater; Roy A Lynch; Michio Asahi; Anthony O Gramolini; Guo-Chang Fan; Dimitris Tsiapras; Harvey S Hahn; Stamatis Adamopoulos; Stephen B Liggett; Gerald W Dorn; David H MacLennan; Dimitrios T Kremastinos; Evangelia G Kranias Journal: J Clin Invest Date: 2003-03 Impact factor: 14.808